What is AI Proteins?
Founded in 2021, AI Proteins operates at the intersection of artificial intelligence and structural biology. The company specializes in de novo protein design, a process that bypasses the limitations of traditional protein engineering by creating novel molecular structures tailored for specific therapeutic functions. By utilizing sophisticated algorithms to predict and synthesize proteins that do not exist in nature, AI Proteins aims to address complex biological challenges that have historically remained intractable.
The company's market position is defined by its ability to rapidly iterate and optimize protein sequences, significantly reducing the time and cost associated with drug discovery. With its headquarters in Andover, Massachusetts, the firm is strategically located within a premier biotech hub, allowing it to tap into a deep pool of scientific talent and collaborative research opportunities. Its focus on synthetic biology places it in a high-growth segment of the life sciences industry, where computational precision is increasingly becoming the standard for pharmaceutical innovation.
How much funding has AI Proteins raised?
AI Proteins has raised a total of $59.7M across 2 funding rounds:
Angel/Seed
$18.2M
Series A
$41.5M
Angel/Seed (2022): $18.2M with participation from Cobro Ventures and Lightchain Capital
Series A (2025): $41.5M led by Cobro Ventures, Mission BioCapital, Lightchain Capital, and Santé Ventures
Key Investors in AI Proteins
Cobro Ventures
Cobro Ventures is a private investment firm specializing in technology and biotechnology sectors, focusing on creating significant value during critical innovation phases through deep operational expertise.
Mission BioCapital
Mission BioCapital is a venture capital firm that provides early-stage capital to innovative life science entrepreneurs, emphasizing mentorship and the acceleration of scientific solutions.
Lightchain Capital
Lightchain Capital is a venture capital fund that specializes in investing in early-stage life sciences companies, with a specific dedication to supporting innovations aimed at improving patient outcomes in cancer treatment.
What's next for AI Proteins?
With the successful closure of this major enterprise-level funding, AI Proteins is well-positioned to advance its lead programs into preclinical validation. The strategic roadmap for the coming quarters involves expanding the company's computational infrastructure and enhancing its wet-lab capabilities to support high-throughput protein synthesis. Furthermore, the firm is expected to pursue strategic partnerships with established pharmaceutical entities to validate its platform across diverse therapeutic indications.
As the biotech sector continues to embrace digital transformation, AI Proteins' ability to deliver bespoke protein solutions will likely attract further interest from both venture capital and corporate strategic investors. The focus remains on scaling the platform's efficiency and demonstrating the clinical utility of its synthetic designs, setting the stage for potential long-term value creation in the oncology and immunology spaces.
